Serendipitous insights involving nonhuman primates

被引:4
作者
Morton, WR [1 ]
Swindler, K
机构
[1] Paris NHP, Edmonds, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] WNPRC, Seattle, WA USA
关键词
nonhuman primate; observation; research; serendipity; synchronicity;
D O I
10.1093/ilar.46.4.346
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Serendipity is discussed as a form of controlled chaos, a phenomenon in a class with synchronicity and other actions affecting research in terms of theory versus observation (e.g., "optional stopping"). Serendipity is a fundamental aspect of basic research, a profitable and normal outcome in the context of "informed observation." The serendipitous finding fits into the following pattern: it is unanticipated, anomalous, and strategic. All observations that have meaning must fit into some context in the observer's mind or suggest a revolutionary new context. It is critically important to maintain access to the resources provided by established primate centers and similar laboratories to capitalize in a timely way on serendipitous findings and to benefit from valuable discoveries made in more directly targeted development investments. Examples are given of serendipitous insights gained in experimentation and observation relative to nonhuman primate research, including both broad and narrow topics. Genomics, which uses comparison-based strategies and capitalizes on the DNA sequences of genetic information, presents what might seem the basis for endless serendipity because nonhuman primates are likely to share most genes present in the human genome. Other topics discussed include infant behavior, birth periodicity, leprosy, cystic fibrosis, environmental enrichment, endocrinology, drug development, and the rapidly expanding study of infectious diseases and pathogen-based bioterrorism.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 31 条
[1]  
[Anonymous], NEW YORK REV BO 1118
[2]  
BEYER J, 2000, ORG BEHAV NEWS FAL, P1
[3]  
BROWN T, 2004, CNS DRUG DEV CLIN TR
[4]  
CAMPBELL WC, 2005, ILAR J, V46, P331
[5]  
CHADER GJ, 2003, WASH ADV GROUP WORKS, P26
[6]  
Di Renzo GC, 2000, PRENAT NEONAT MED, V5, P1
[7]  
FIDOCK DA, 2004, NAT REV DRUG DISCOV, V3, P3
[8]  
Fine GaryAlan., 1996, QUALITATIVE STUDIES, V9, P434, DOI [10.1080/0951839960090405, DOI 10.1080/0951839960090405]
[9]  
GORMUS BJ, 1988, INT J LEPROSY, V56, P61
[10]  
JESSEN T, 2000, DRUG DISC TODAY S, V5, P48